<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294109</url>
  </required_header>
  <id_info>
    <org_study_id>17-000598</org_study_id>
    <nct_id>NCT03294109</nct_id>
  </id_info>
  <brief_title>Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy</brief_title>
  <official_title>Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A blinded randomized control trial in living kidney donors. The study group will receive a&#xD;
      liposomal bupivacaine Trans Quadratus Lumborum (TQL) block after the induction of general&#xD;
      anesthesia. The following study variables will be collected postoperatively following arrival&#xD;
      in the post-anesthesia care unit. Current and maximum intensity pain scores will be&#xD;
      documented by nurses in Electronic Health Record (EHR). Total opiate dose consumed every 24&#xD;
      hours will be collected from the EHR and pain diary after discharge. Patient satisfaction&#xD;
      will be evaluated using the Revised American Pain Society Patient Outcome Questionnaire&#xD;
      (APS-POQ-R) 24 hours' post-procedure. Incidence of nausea will be extracted from nursing&#xD;
      notes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a blinded (patients are blinded and all the staff and the nurses who collect data are&#xD;
      also blinded) randomized controlled trial in living kidney donors who have been approved by a&#xD;
      multidisciplinary (nephrology, urology, psychiatry, and social work) team to proceed with&#xD;
      donor nephrectomy. Patients will be approached to participate in the study only after they&#xD;
      have agreed to kidney donation and have been informed of all of the associated risks.&#xD;
      Participants are informed that they can withdraw from kidney donation at any time until they&#xD;
      are in the operating room.&#xD;
&#xD;
      Patients meeting these criteria, who also consent to participate in the study, will be&#xD;
      randomized (standard of care pain medication vs TQL block). The ratio of male to female&#xD;
      patients in each arm will be equal because of the known increased risks for post-operative&#xD;
      nausea/vomiting (PONV) in females. The study group will receive a liposomal bupivacaine TQL&#xD;
      block after the induction of general anesthesia and liposomal bupivacaine transverse&#xD;
      abdominis plane (TAP) block after closure of the midline fascia. All patients including the&#xD;
      control group will have infiltration of the skin edges with bupivacaine. Control patients&#xD;
      will have a TAP block with 5 cc of bupivacaine on both sides. A placebo 22g needle will be&#xD;
      placed at the same site as the TQL block without injection. Intra-operative narcotics will be&#xD;
      administered by the anesthesia team based on standard criteria. All participants will receive&#xD;
      intravenous ketorolac and acetaminophen at the end of the procedure. Intravenous ketorolac&#xD;
      will be continued for 24 hours while hospitalized. Post-operative pain management with&#xD;
      intermittent parenteral and enteral narcotics as needed will be the same in both groups.&#xD;
&#xD;
      Liposomal bupivacaine block administration:&#xD;
&#xD;
      After induction of general anesthesia, surgical team will turn the patient to the lateral&#xD;
      position (final position for surgery). After prep with and drape, investigators will place&#xD;
      ultrasound probe in mid- posterior axillary line, just above iliac crest. The investigators&#xD;
      will identify abdominal wall muscles including external oblique, internal oblique, transverse&#xD;
      abdominis, and quadratus lumborum as well as thoracolumbar fascia with the help of&#xD;
      ultrasound. Then, investigators will insert a 22g nerve block needle and advanced it under&#xD;
      direct guidance of ultrasound until it is below the fascial covering of the quadratus&#xD;
      lumborum muscle layer or its fascia which forms a continuous fascia compartment with&#xD;
      thoracolumbar fascia. After aspiration to rule out intravascular location of the needle,&#xD;
      investigators will be inject 20 mL of liposomal bupivacaine mixed with 10ml of normal saline&#xD;
      under ultrasound guidance, to monitor spread of the injected fluid . The investigators will&#xD;
      aspirate repeatedly every 5cc of local anesthetic. The investigators will remove the needle&#xD;
      upon completion of the injection.&#xD;
&#xD;
      The following study variables will be collected postoperatively following arrival in the&#xD;
      post-anesthesia care unit. Current and maximum intensity pain scores will be documented by&#xD;
      nurses in EHR. Total opiate dose consumed every 24 hours will be collected from the EHR and&#xD;
      pain diary after discharge. Patient satisfaction will be evaluated using the Revised American&#xD;
      Pain Society Patient Outcome Questionnaire (APS-POQ-R) 24 hours' post-procedure. Incidence of&#xD;
      nausea will be extracted from nursing notes&#xD;
&#xD;
      Complications will be documented by anesthesia pain service that will follow these patients&#xD;
      while admitted.&#xD;
&#xD;
      Outpatient use of narcotics, pain assessment, bowel function, sexual function complications&#xD;
      from the block or the donor surgery, and attitudes toward kidney donation will be evaluated&#xD;
      with validated survey instruments. Please see the timeline for the collection of the data&#xD;
      prior to and after kidney donation. The survey data will be collected using secure links to a&#xD;
      REDCap server 3, 5, 10, 30, and 90 days after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">June 24, 2020</completion_date>
  <primary_completion_date type="Actual">June 24, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Score</measure>
    <time_frame>3 days post-op</time_frame>
    <description>Visual Analog Score (VAS) for pain, scores range from 0-10, with lower scores indicating lower pain level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Pain Management</measure>
    <time_frame>Day 1</time_frame>
    <description>The Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) survey score on variable &quot;Satisfaction with Pain Treatments.&quot; This is a scale ranging from 0-10, with 0 being extremely dissatisfied, a poor outcome, with pain treatment to 10 being extremely satisfied, a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea and Vomiting, Defined as Requiring Pre-op Scopolamine Patch or Rescue Antiemetics</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of patients requiring pre-op scopolamine patch, and number of patients requiring rescue antiemetics in PACU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return of Bowel Function</measure>
    <time_frame>Day 5</time_frame>
    <description>Bowl activity survey asked participants how big a problem the bowel function was after surgery, on a scale of 1 (no problem) to 5 (a big problem).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications Related to Surgery or Block</measure>
    <time_frame>Duration of inpatient stay, up to 5 days</time_frame>
    <description>Number of complications related to surgery or block in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Use Dose/Day</measure>
    <time_frame>Day 3</time_frame>
    <description>Milligram Morphine Equivalent /day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Analgesics, Opioid</condition>
  <condition>Analgesics, Non-Narcotic</condition>
  <condition>Physiological Effects of Drugs</condition>
  <condition>Peripheral Nervous System Agents</condition>
  <condition>Patient Satisfaction</condition>
  <condition>Return to Work</condition>
  <condition>Activity, Sexual</condition>
  <arm_group>
    <arm_group_label>study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>liposomal bupivacain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abdominal wall block with liposomal bupivicaine</intervention_name>
    <description>Abdominal wall block with liposomal bupivicaine</description>
    <arm_group_label>study</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing laparoscopic donor nephrectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Systemic or local infection at the potential block site.&#xD;
&#xD;
          -  Allergy or hypersensitivity to the local anesthetic,&#xD;
&#xD;
          -  Possible variations in surgical approach to donor nephrectomy other than what is&#xD;
             defined in this protocol.&#xD;
&#xD;
          -  Scarring or anatomic abnormality over the proposed injection site&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siamak Rahman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans a Gritsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connie Frank Kidney Transplant Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1016/j.jclinane.2015.05.006</url>
    <description>Quadratus lumborum block: an effective method of perioperative analgesia in children undergoing pyeloplasty</description>
  </link>
  <reference>
    <citation>Wikner M. Unexpected motor weakness following quadratus lumborum block for gynaecological laparoscopy. Anaesthesia. 2017 Feb;72(2):230-232. doi: 10.1111/anae.13754. Epub 2016 Nov 28.</citation>
    <PMID>27891579</PMID>
  </reference>
  <reference>
    <citation>Dam M, Moriggl B, Hansen CK, Hoermann R, Bendtsen TF, Børglum J. The Pathway of Injectate Spread With the Transmuscular Quadratus Lumborum Block: A Cadaver Study. Anesth Analg. 2017 Jul;125(1):303-312. doi: 10.1213/ANE.0000000000001922.</citation>
    <PMID>28277325</PMID>
  </reference>
  <reference>
    <citation>Blanco R, Ansari T, Girgis E. Quadratus lumborum block for postoperative pain after caesarean section: A randomised controlled trial. Eur J Anaesthesiol. 2015 Nov;32(11):812-8. doi: 10.1097/EJA.0000000000000299.</citation>
    <PMID>26225500</PMID>
  </reference>
  <reference>
    <citation>Børglum J, Gögenür I, Bendtsen TF. Abdominal wall blocks in adults. Curr Opin Anaesthesiol. 2016 Oct;29(5):638-43. doi: 10.1097/ACO.0000000000000378. Review.</citation>
    <PMID>27429253</PMID>
  </reference>
  <reference>
    <citation>Hansen CK, Dam M, Bendtsen TF, Børglum J. Ultrasound-Guided Quadratus Lumborum Blocks: Definition of the Clinical Relevant Endpoint of Injection and the Safest Approach. A A Case Rep. 2016 Jan 15;6(2):39. doi: 10.1213/XAA.0000000000000270.</citation>
    <PMID>26771297</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <results_first_submitted>July 22, 2021</results_first_submitted>
  <results_first_submitted_qc>October 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Siamak Rahman, MD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>TQL block, TAP block, donor nephrectomy, pain, patient satisfaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03294109/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Prior to randomization, 146 patients signed consent. Of those 146, 137 completed the intake questionnaire, a requirement for the study. Of those 137, 103 were scheduled for surgery.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study</title>
          <description>ERAS Plus laparoscopic TAP block and transmuscular quadratus lumbarum with liposomal bupivicaine:</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>ERAS Plus laparoscopic TAP block</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Underwent Surgery</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study</title>
          <description>ERAS Plus laparoscopic TAP block and transmuscular quadratus lumbarum with liposomal bupivicaine</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>ERAS Plus laparoscopic TAP block</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Score</title>
        <description>Visual Analog Score (VAS) for pain, scores range from 0-10, with lower scores indicating lower pain level</description>
        <time_frame>3 days post-op</time_frame>
        <population>Participants who completed pain VAS survey on day 3</population>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>ERAS Plus laparoscopic TAP block and transmuscular quadratus lumbarum with liposomal bupivicaine</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ERAS Plus laparoscopic TAP block</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Score</title>
          <description>Visual Analog Score (VAS) for pain, scores range from 0-10, with lower scores indicating lower pain level</description>
          <population>Participants who completed pain VAS survey on day 3</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" spread="1.94"/>
                    <measurement group_id="O2" value="4.62" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Pain Management</title>
        <description>The Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) survey score on variable &quot;Satisfaction with Pain Treatments.&quot; This is a scale ranging from 0-10, with 0 being extremely dissatisfied, a poor outcome, with pain treatment to 10 being extremely satisfied, a better outcome.</description>
        <time_frame>Day 1</time_frame>
        <population>Patients who completed APS-POQ-R survey question &quot;Satisfaction with Pain Treatments&quot; on Day 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>ERAS Plus laparoscopic TAP block and transmuscular quadratus lumbarum with liposomal bupivicaine</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ERAS Plus laparoscopic TAP block</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Pain Management</title>
          <description>The Revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R) survey score on variable &quot;Satisfaction with Pain Treatments.&quot; This is a scale ranging from 0-10, with 0 being extremely dissatisfied, a poor outcome, with pain treatment to 10 being extremely satisfied, a better outcome.</description>
          <population>Patients who completed APS-POQ-R survey question &quot;Satisfaction with Pain Treatments&quot; on Day 1.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="1.9"/>
                    <measurement group_id="O2" value="9.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea and Vomiting, Defined as Requiring Pre-op Scopolamine Patch or Rescue Antiemetics</title>
        <description>Number of patients requiring pre-op scopolamine patch, and number of patients requiring rescue antiemetics in PACU.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>ERAS Plus laparoscopic TAP block and transmuscular quadratus lumbarum with liposomal bupivicaine</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ERAS Plus laparoscopic TAP block</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea and Vomiting, Defined as Requiring Pre-op Scopolamine Patch or Rescue Antiemetics</title>
          <description>Number of patients requiring pre-op scopolamine patch, and number of patients requiring rescue antiemetics in PACU.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-op Scopolamine patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rescue antiemetics in PACU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Return of Bowel Function</title>
        <description>Bowl activity survey asked participants how big a problem the bowel function was after surgery, on a scale of 1 (no problem) to 5 (a big problem).</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>ERAS Plus laparoscopic TAP block and transmuscular quadratus lumbarum with liposomal bupivicaine:</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ERAS Plus laparoscopic TAP block</description>
          </group>
        </group_list>
        <measure>
          <title>Return of Bowel Function</title>
          <description>Bowl activity survey asked participants how big a problem the bowel function was after surgery, on a scale of 1 (no problem) to 5 (a big problem).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1"/>
                    <measurement group_id="O2" value="1.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications Related to Surgery or Block</title>
        <description>Number of complications related to surgery or block in each group</description>
        <time_frame>Duration of inpatient stay, up to 5 days</time_frame>
        <population>All enrolled patients receiving surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>ERAS Plus laparoscopic TAP block and transmuscular quadratus lumbarum with liposomal bupivicaine</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ERAS Plus laparoscopic TAP block</description>
          </group>
        </group_list>
        <measure>
          <title>Complications Related to Surgery or Block</title>
          <description>Number of complications related to surgery or block in each group</description>
          <population>All enrolled patients receiving surgery</population>
          <units>Complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Use Dose/Day</title>
        <description>Milligram Morphine Equivalent /day</description>
        <time_frame>Day 3</time_frame>
        <population>Patients whom responded to survey on Day 3</population>
        <group_list>
          <group group_id="O1">
            <title>Study</title>
            <description>ERAS Plus laparoscopic TAP block and transmuscular quadratus lumbarum with liposomal bupivicaine</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ERAS Plus laparoscopic TAP block</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Use Dose/Day</title>
          <description>Milligram Morphine Equivalent /day</description>
          <population>Patients whom responded to survey on Day 3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 MME</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;0 - 5 MMe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;5 - 10 MME</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10-15 MME</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;15-20 MME</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 MME</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During hospitalization, up to 5 days</time_frame>
      <desc>Complications from surgery were collected as adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Study</title>
          <description>ERAS Plus laparoscopic TAP block and transmuscular quadratus lumbarum with liposomal bupivicaine</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>ERAS Plus laparoscopic TAP block</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Post-operative hypotension in setting of acute blood loss</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Contralateral flank pain and acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Wound seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion requiring aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Siamak Rahman, MD</name_or_title>
      <organization>university of Californiia</organization>
      <phone>310 2678839</phone>
      <email>sirahman@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

